Urine drug testing and other definitive drug assays are not intended for routine administrative or screening-only uses. The policy expressly excludes testing performed as a condition of employment or pre‑employment, participation in school or community athletics or extracurricular activities, and screening for medico‑legal purposes (unless required by state regulation). Also excluded are screening of asymptomatic patients (except where the policy lists covered indications), testing as part of routine physicals or other administrative exams (for example, enrollment or insurance eligibility), blanket orders or routine standing orders for all patients, reflex definitive testing following point‑of‑care presumptive testing, and specimen validity/adulteration testing which is considered a laboratory quality control activity.

Certain CPT/HCPCS codes are identified in this policy as not supporting the coverage criteria and therefore may be denied when billed. Examples called out in the policy include CPT codes 0054U, 0082U, and 0328U; these represent very large definitive panels and are listed under “CPT Codes That Do Not Support Coverage Criteria.”

The policy lists several contexts that are specifically considered not medically necessary and not appropriate reasons for ordering definitive drug testing. These include testing required for employment or pre‑employment, screening for school or community athletic participation, court‑ordered or other medico‑legal screening (unless state regulations mandate it), asymptomatic population screening outside the policy’s covered indications, testing performed as part of routine physicals or other administrative exams, and blanket or standing orders that apply to all patients.

Definitive assays billed as supporting medical necessity must meet required methodological quality standards. Tests performed without method‑ or drug‑specific calibration, without matrix‑matched quality control material, or without use of stable isotope or other universally recognized internal standards for each analyte are identified in the policy (see HCPCS G0659) as not meeting the policy’s methodological requirements and therefore do not support coverage criteria.

Tests billed with CPT codes 0054U, 0082U, or 0328U and HCPCS codes G0482 or G0483 are listed in this policy as not supporting the coverage criteria and therefore may be denied when submitted for outpatient definitive drug testing. CPT 0054U, 0082U, and 0328U describe very large-panel definitive assays (e.g., 14 or more classes, 90 or more drugs, 120 or more drugs/metabolites) that the policy explicitly places in the “CPT Codes That Do Not Support Coverage Criteria” group. HCPCS codes G0482 and G0483 correspond to per-day definitive testing for 15–21 and 22 or more drug class(es), respectively, and are likewise listed as not supporting the coverage criteria.

Definitive assays performed without method- or drug-specific calibration, without matrix-matched quality control material, or without the use of stable isotope or other universally recognized internal standard(s) for each drug/drug class are identified in this policy as unsupported for coverage. The policy describes HCPCS code G0659 for definitive testing performed without these required calibration/quality-control elements and indicates such tests do not meet the methodologic standards required for coverage.

Urine drug testing is used clinically to assist diagnosis, to monitor adherence to prescribed controlled substances, and to detect misuse. The policy differentiates between initial immunoassay‑based presumptive screens, which are commonly used at point of care but can yield false positives or negatives, and laboratory definitive methods (for example, GC/MS and LC‑MS/MS) that provide specific identification and/or quantification of drugs and metabolites. Definitive testing is reserved for situations such as resolving unexpected or inconsistent presumptive results, obtaining quantitative levels for clinical decision‑making, or measuring serum therapeutic drug levels tied to treatment.

Large‑panel definitive tests that report very high numbers of drugs (for example the wide panels described in the CPT entries cited in this policy) are listed under CPT Codes That Do Not Support Coverage Criteria and are not supported for coverage under this policy.

As noted elsewhere in the policy, tests billed with CPT codes 0054U, 0082U, or 0328U, or HCPCS codes G0482 or G0483, are categorized as not supporting the coverage criteria and therefore may be denied.

The policy states that definitive testing performed without essential methodologic safeguards—specifically without method‑ or drug‑specific calibration, without matrix‑matched quality control materials, or without use of stable isotope or other universally recognized internal standards for each analyte—does not support coverage and is identified in the policy as not covered (see HCPCS G0659).